Patient characteristics
| Patient . | Sex . | Age, y . | Diagnosis . | Year SS of diagnosis . | ISCL classification . | Leukocytes (×1000/µL blood) . | CD4:CD8 ratio . | TCR clone . | Current treatment . | Previous treatment . |
|---|---|---|---|---|---|---|---|---|---|---|
| SS01 | F | NA | SS | NA | NA | NA | 93.5* | NA | NA | NA |
| SS02 | M | 67 | SS | 2016 | B2 | 2.4 | 9.2 | Yes (BM, Skin) | ECP, IFN-α, Bexarotene, TSEI | Acitretin, Klorokin, Doxycyklin, Prednisolone |
| SS03 | M | 79 | SS | 2016 | B2 | 4.1 | 16.6 | Yes (BM, Blood, Skin) | ECP | Ifliximab, Etanercept, Adalimumab, Ustekinumab, Cyclosporin, PUVA |
| SS04 | M | 85 | SS | 2012 | NA | NA | 32.4* | Yes (BM, Blood, Skin) | ECP, IFN-α | PUVA, IFN-α, Bexarotene |
| SS05 | F | 74 | SS | 2016 | B2 | 85.5 | 90.0 | Yes (BM, Blood, Skin) | ECP† | Prednisolone, Metotrexate, PUVA |
| SS06 | M | NA | SS | 2013 | B2 | NA | 35.2 | Yes (Blood‡) | NA† | NA |
| SS07 | F | 79 | SS | 2016 | B2 | 4 | 30.0 | Yes (BM, Blood, Skin) | ECP, Acitretin | Metotrexate, Allitretionin, Azathioprin, Acitretin |
| SS08 | M | 65 | SS | 2016 | B2 | 1.7 | 16.5 | Yes (BM, Blood, Skin) | ECP, IFN-α, Prednisolone | Ifliximab, Ustekinumab, Secukinumab, Adalimumab, Acitretin, Allitretionin, Prednisolone |
| SS09 | M | 58 | SS | 2018 | B2 | 1.3 | 13.0 | Yes (Blood, LN) | ECP, IFN-α, Prednisolone | Prednisolone, Metotrexate |
| SS10 | M | 80 | SS | 2018 | B2 | 8.1 | 28.0 | Yes (BM, Blood, Skin) | ECP, IFN-α† | PUVA |
| SS11 | M | 76 | SS | 2017 | B2 | 3.3 | 26.0 | Yes (BM, Blood, Skin) | ECP, IFN-α, Bexarotene | PUVA, UVB, Methotrexate, IFN-α, Bexarotene |
| Patient . | Sex . | Age, y . | Diagnosis . | Year SS of diagnosis . | ISCL classification . | Leukocytes (×1000/µL blood) . | CD4:CD8 ratio . | TCR clone . | Current treatment . | Previous treatment . |
|---|---|---|---|---|---|---|---|---|---|---|
| SS01 | F | NA | SS | NA | NA | NA | 93.5* | NA | NA | NA |
| SS02 | M | 67 | SS | 2016 | B2 | 2.4 | 9.2 | Yes (BM, Skin) | ECP, IFN-α, Bexarotene, TSEI | Acitretin, Klorokin, Doxycyklin, Prednisolone |
| SS03 | M | 79 | SS | 2016 | B2 | 4.1 | 16.6 | Yes (BM, Blood, Skin) | ECP | Ifliximab, Etanercept, Adalimumab, Ustekinumab, Cyclosporin, PUVA |
| SS04 | M | 85 | SS | 2012 | NA | NA | 32.4* | Yes (BM, Blood, Skin) | ECP, IFN-α | PUVA, IFN-α, Bexarotene |
| SS05 | F | 74 | SS | 2016 | B2 | 85.5 | 90.0 | Yes (BM, Blood, Skin) | ECP† | Prednisolone, Metotrexate, PUVA |
| SS06 | M | NA | SS | 2013 | B2 | NA | 35.2 | Yes (Blood‡) | NA† | NA |
| SS07 | F | 79 | SS | 2016 | B2 | 4 | 30.0 | Yes (BM, Blood, Skin) | ECP, Acitretin | Metotrexate, Allitretionin, Azathioprin, Acitretin |
| SS08 | M | 65 | SS | 2016 | B2 | 1.7 | 16.5 | Yes (BM, Blood, Skin) | ECP, IFN-α, Prednisolone | Ifliximab, Ustekinumab, Secukinumab, Adalimumab, Acitretin, Allitretionin, Prednisolone |
| SS09 | M | 58 | SS | 2018 | B2 | 1.3 | 13.0 | Yes (Blood, LN) | ECP, IFN-α, Prednisolone | Prednisolone, Metotrexate |
| SS10 | M | 80 | SS | 2018 | B2 | 8.1 | 28.0 | Yes (BM, Blood, Skin) | ECP, IFN-α† | PUVA |
| SS11 | M | 76 | SS | 2017 | B2 | 3.3 | 26.0 | Yes (BM, Blood, Skin) | ECP, IFN-α, Bexarotene | PUVA, UVB, Methotrexate, IFN-α, Bexarotene |
BM, bone marrow; ECP, extracorporal photopheresis; IFN, interferon; LN, lymph node; NA, Not available; PUVA, psoralen and ultraviolet A; and TSEI, total skin electron irradiation.
Measured after initiation of treatment.
Cells from these patients were collected before initiation of SS treatment.
Detected by flow cytometry